Editorial team of Nature Reviews Drug Discovery
www.nature.com/nrd
Nature Reviews Drug Discovery
Loading...
Novel drug targets in 2025
www.nature.com/articles/d41...
This new article highlights 11 targets not previously modulated by approved drugs
Antiviral peptide nabs FDA approval for hepatitis delta virus infection
www.nature.com/articles/d41...
Gilead’s bulevirtide is the first treatment for the potentially fatal infection
For readers interested in next-generation GLP-1-based therapies for diabetes, obesity and more, here's a review
nature.com/articles/s41...
rdcu.be/fnl3W
A guide to effective drug development through nonprofit models
www.nature.com/articles/d41...
Patient organizations are reshaping rare disease drug development. Based on a survey, interviews and experience, this article discusses how to direct resources toward drug development goals
Our June issue is live! Read about the therapeutic potential of orphan GPCRs, wearable technologies in clinical trials for drug development, a renaissance in targeting the PI3K/AKT/mTOR pathway and more here www.nature.com/nrd/volumes/...
Towards mRNA therapeutics 2.0
www.nature.com/articles/s41...
This new Review discusses progress and insights from clinical studies on mRNA-based drugs, including enzyme replacement therapies, cancer immunotherapies, genome-modifying therapies and immune cell reprogramming therapies
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments. www.statnews.com/2026/06/08/a...
Evolution of the psoriasis therapy landscape
www.nature.com/articles/d41...
This new article analyses the pipeline of drugs for psoriasis and their market impact, highlighting the growing importance of oral therapies
Better data for better medicines: a path to data-driven medicines regulation
www.nature.com/articles/d41...
This new Comment article highlights how the EU medicines regulatory system is becoming more data-driven
Therapeutic and prophylactic strategies for Ebola caused by Bundibugyo virus
www.nature.com/articles/d41...
This new article argues that the ongoing Ebola outbreak should be a turning point for moving R&D towards species-inclusive and broadly applicable filovirus countermeasures
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
